Clinical Trials
61 trialsNCT02583893 2026-05-29
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
Thomas Jefferson University
Phase 2 Completed
NCT02523976 2026-02-11
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT03839446 2025-02-20
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
University of Pittsburgh
Phase 2 Completed
NCT00004197 2023-09-07
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02686593 2022-10-06
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
The University of Hong Kong
Phase 2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00712582 2022-06-21
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00290511 2022-04-22
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03012672 2022-03-08
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
University of Washington
Phase 2 Completed
NCT00193479 2022-03-03
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01186640 2022-01-05
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
German CLL Study Group
Phase 2 Completed
NCT02756572 2021-11-08
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
University of Washington
Phase 2 Completed
NCT00015951 2019-10-17
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
University of Maryland, Baltimore
Phase 2 Completed
NCT01204710 2019-09-20
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00169208 2019-08-28
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
Lymphoma Study Association
Phase 2 Completed
NCT00254410 2019-05-01
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00458848 2019-02-15
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT01133158 2018-11-01
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00795002 2018-08-07
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00274963 2018-05-11
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 2 Completed
NCT00278213 2018-05-11
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
German CLL Study Group
Phase 2 Completed
NCT00005985 2017-11-29
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01349972 2017-07-31
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00186875 2017-07-28
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00182741 2017-05-03
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00017563 2017-04-28
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00079105 2017-03-30
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
Newcastle-upon-Tyne Hospitals NHS Trust
Phase 2 Completed
NCT00058084 2017-02-23
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00661492 2016-12-09
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
US Oncology Research
Phase 2 Completed
NCT00656084 2016-11-03
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
US Oncology Research
Phase 2 Completed
NCT00079482 2016-07-21
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01523860 2016-03-01
FLE09
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT00124566 2016-01-18
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Eisai Inc.
Phase 2 Completed
NCT00407966 2015-08-04
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00634244 2015-07-07
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01004497 2015-05-29
ALL
The Catholic University of Korea
Phase 2 Completed
NCT00109837 2015-03-25
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00683475 2014-10-16
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00002805 2014-07-24
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Children's Oncology Group
Phase 2 Completed
NCT00119730 2014-04-24
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00070174 2014-02-20
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
Children's Oncology Group
Phase 2 Completed
NCT00774046 2014-02-11
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
University of Chicago
Phase 2 Completed
NCT00004237 2013-11-06
Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00100477 2013-09-25
Use of Topotecan in Patients With Refractory Acute Leukemia
VA Office of Research and Development
Phase 2 Completed
NCT00337246 2013-08-02
Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00842595 2013-07-24
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00002598 2013-06-25
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002474 2013-05-30
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003957 2013-04-17
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Fox Chase Cancer Center
Phase 2 Completed